Literature DB >> 28740706

Upstaging, not just a non-small matter.

Daniel C Thomas1, Anthony W Kim2.   

Abstract

Year:  2017        PMID： 28740706      PMCID： PMC5506163          DOI： 10.21037/jtd.2017.05.64

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  30 in total

1.  Surgical resection should be considered for stage I and II small cell carcinoma of the lung.

Authors:  Benny Weksler; Katie S Nason; Manisha Shende; Rodney J Landreneau; Arjun Pennathur
Journal:  Ann Thorac Surg       Date:  2012-03-17       Impact factor: 4.330

2.  Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base.

Authors:  Susan E Combs; Jacquelyn G Hancock; Daniel J Boffa; Roy H Decker; Frank C Detterbeck; Anthony W Kim
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

3.  Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up.

Authors:  W Fox; J G Scadding
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

4.  Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

Authors:  Charles M Rudin; Nofisat Ismaila; Christine L Hann; Narinder Malhotra; Benjamin Movsas; Kim Norris; M Catherine Pietanza; Suresh S Ramalingam; Andrew T Turrisi; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis.

Authors:  John M Varlotto; Abram Recht; John C Flickinger; Laura N Medford-Davis; Anne-Marie Dyer; Malcolm M DeCamp
Journal:  J Thorac Cardiovasc Surg       Date:  2011-09       Impact factor: 5.209

6.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Authors:  Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

7.  Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.

Authors:  Heather A Wakelee; Patricia Stephenson; Steven M Keller; Henry Wagner; Arnold Herskovic; Ritsuko Komaki; Randolph S Marks; Michael C Perry; Robert B Livingston; David H Johnson
Journal:  Lung Cancer       Date:  2005-01-05       Impact factor: 5.705

8.  Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?

Authors:  David Schreiber; Justin Rineer; Jeremy Weedon; Dan Vongtama; Angela Wortham; Anne Kim; Peter Han; Kwang Choi; Marvin Rotman
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

9.  The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

Authors:  Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

10.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.